LEXINGTON, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Aegis Conference to be held virtually on May 2-4, 2023.
Ms. Curley will present on Thursday, May 4, 2023, at 4:30 p.m. ET. To attend, please join here.
For more information about the conference, or to schedule a one-on-one meeting with iSpecimen’s management team, please contact your appropriate Aegis representative, or send an email to Aegis at This email address is being protected from spambots. You need JavaScript enabled to view it. or KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Allison Soss
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contacts
KCSA Strategic Communications
Raquel Cona / Michaela Fawcett
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.00 |
Daily Change: | 0.04 1.35 |
Daily Volume: | 2,418,488 |
Market Cap: | US$2.890M |
December 20, 2024 December 13, 2024 December 12, 2024 November 07, 2024 November 07, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB